Article: SMITHKLINE BEECHAM'S AUGMENTIN CLEARED IN U.S. FOR MORE CONVENIENT DOSING REGIMEN FOR ADULTS

Of Drug Widely Used In Fight Against Resistant Bacteria

PHILADELPHIA, Feb. 12 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH, SBE)(SB) announced today that it has received U.S. marketing clearance for a new, more convenient adult dosing regimen of Augmentin (amoxicillin/clavulanate potassium), one of the most frequently used antibiotics for infections involving drug-resistant bacteria.

In the new regimen, Augmentin is administered twice a day (BID), every 12 hours, in contrast to the three-times-a-day (TID), every-8-hour regimen used since the introduction of Augmentin in the U.S. 11 years ago.

In addition to affording more convenience, the new regimen ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!